# A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition

> **NCT00287066** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 22 (—)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Inhaled Human Insulin
- **DRUG:** Regular Human Insulin

## Key facts

- **NCT ID:** NCT00287066
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-02
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** 22 (—)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2008-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00287066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00287066, "A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00287066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*